In today’s session Sarepta Therapeutics Inc (SRPT) registered an unusually high (561) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious SRPT increase. With 561 contracts traded and 3404 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: SRPT161118C00043000 closed last at: $2.05 or 241.7% up. About 806,639 shares traded hands. Sarepta Therapeutics Inc (NASDAQ:SRPT) has risen 82.38% since April 11, 2016 and is uptrending. It has outperformed by 76.24% the S&P500.
Sarepta Therapeutics Inc (NASDAQ:SRPT) Ratings Coverage
Out of 21 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 12 rate it a “Buy”, 1 “Sell”, while 8 “Hold”. This means 57% are positive. $108 is the highest target while $4 is the lowest. The $53.82 average target is 33.75% above today’s ($40.24) stock price. Sarepta Therapeutics has been the topic of 52 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Roth Capital given on Wednesday, August 26. Roth Capital maintained Sarepta Therapeutics Inc (NASDAQ:SRPT) rating on Wednesday, August 5. Roth Capital has “Buy” rating and $45 price target. The firm has “Outperform” rating by Credit Suisse given on Tuesday, October 18. The rating was upgraded by Piper Jaffray to “Overweight” on Monday, August 24. The firm has “Hold” rating given on Monday, September 19 by Jefferies. RBC Capital Markets maintained it with “Outperform” rating and $108 target price in Wednesday, September 28 report. The firm has “Buy” rating given on Thursday, August 27 by Robert W. Baird. The stock has “Perform” rating given by Oppenheimer on Tuesday, April 26. RBC Capital Markets maintained Sarepta Therapeutics Inc (NASDAQ:SRPT) on Friday, October 28 with “Outperform” rating. The stock has “Neutral” rating given by Wedbush on Thursday, April 21.
According to Zacks Investment Research, “Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company’s diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma, Inc., is headquartered in Bothell, Washington.”
Insitutional Activity: The institutional sentiment increased to 1.16 in 2016 Q2. Its up 0.32, from 0.84 in 2016Q1. The ratio improved, as 31 funds sold all Sarepta Therapeutics Inc shares owned while 32 reduced positions. 31 funds bought stakes while 42 increased positions. They now own 33.70 million shares or 3.23% less from 34.83 million shares in 2016Q1.
Voya Investment Mngmt Limited Liability Co holds 18,231 shares or 0% of its portfolio. Oppenheimer Com accumulated 0.01% or 20,213 shares. California State Teachers Retirement Sys has 0% invested in the company for 89,609 shares. Emerald Advisers Pa holds 0.22% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 235,506 shares. Mizuho Secs Usa owns 174,400 shares or 0.53% of their US portfolio. Great West Life Assurance Can owns 4,935 shares or 0% of their US portfolio. Swiss State Bank has invested 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT). Century Companies owns 34,156 shares or 0% of their US portfolio. Geduld E E, a New York-based fund reported 25,000 shares. Hightower Lc has invested 0.01% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT). Morgan Stanley accumulated 967,727 shares or 0.01% of the stock. Pub Employees Retirement Association Of Colorado last reported 12,338 shares in the company. Cibc accumulated 0% or 27,745 shares. Jpmorgan Chase & Com accumulated 0% or 570 shares. Advisers Lc last reported 0.01% of its portfolio in the stock.
Insider Transactions: Since September 14, 2016, the stock had 0 insider buys, and 8 selling transactions for $8.94 million net activity. On Monday, September 19 Kaye Edward M. MD sold $1.22M worth of the stock or 24,352 shares. On Monday, September 19 the insider Howton David T sold $465,200. Ruff Shamim sold $438,660 worth of stock or 7,311 shares. 30,000 shares with value of $1.50M were sold by Mahatme Sandesh on Monday, October 17. Aphale Jayant had sold 35,000 shares worth $1.75 million on Monday, September 19.
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The company has a market cap of $2.11 billion. The Firm is focused on the discovery and development of ribonucleic acid -targeted therapeutics for the treatment of rare, infectious and other diseases. It currently has negative earnings. The Firm operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
SRPT Company Profile
Sarepta Therapeutics, Inc., incorporated on June 5, 2013, is a biopharmaceutical company. The Firm is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Firm is engaged in the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Firm is primarily focused on advancing the development of its disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. The Firm is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.
More important recent Sarepta Therapeutics Inc (NASDAQ:SRPT) news were published by: Profitconfidential.com which released: “Sarepta Therapeutics Inc: $40.00 Is Price Support on SRPT stock” on October 30, 2016, also Businesswire.com published article titled: “Sarepta Therapeutics to Present Company Overview at the Credit Suisse 25th …”, Forbes.com published: “Oversold Conditions For Sarepta Therapeutics (SRPT)” on November 02, 2016. More interesting news about Sarepta Therapeutics Inc (NASDAQ:SRPT) was released by: Benzinga.com and their article: “3 Reasons 2017 Launch Expectations For Sarepta’s EXONDYS 51 Are ‘Too High'” with publication date: November 11, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.